Ghrelin Deacylase as a Treatment for Opioid Polysubstance Abuse
生长素释放肽脱酰酶治疗阿片类多物质滥用
基本信息
- 批准号:10510245
- 负责人:
- 金额:$ 170.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAftercareAlcoholsAmino AcidsAmphetaminesAnimalsAttenuatedBehaviorBindingBiological AssayBlood CirculationBrainButyrylcholinesteraseChimeric ProteinsChronicCocaineDR1 geneDataDependenceDevelopmentDiseaseDopamineDopamine ReceptorDown-RegulationDrug ExposureDrug abuseEnzymesEsthesiaEuphoriaFeelingFentanylG-Protein-Coupled ReceptorsGastric AcidHeroinHigh PrevalenceHumanHydrolaseHyperactivityHypesthesiaIn VitroIngestionInvestigationLeadLigandsLiteratureMethamphetamineMorphineNational Institute of Drug AbuseNeuronsNicotineOctanoic AcidsOpioidPathway interactionsPeptidesPerceptionPharmaceutical PreparationsPlayPresynaptic TerminalsProcessProductionPropertyProteinsRattusReceptor SignalingRecombinant ProteinsRelapseReportingResearchRewardsRodentRodent ModelRoleSelf AdministrationSideSignal TransductionSite-Directed MutagenesisSomatotropinStimulantStimulusStomachStructureSubstance Use DisorderSubstance of AbuseSynapsesSystemTestingTherapeuticTravelWithdrawalWorkanimal dataantagonistbasebehavioral studyconditioned place preferencedeacylationdesigndopamine systemdopamine transporterdopaminergic neurondrug rewardeffective therapyenzyme activityghrelingrowth hormone secretagogue receptorimprovedin vivoin vivo evaluationmethamphetamine effectmethamphetamine usemutantnovelnovel therapeutic interventionnovel therapeuticsopioid use disorderopioid userpleasurepolysubstance abusepolysubstance useprotein expressionprotein purificationrational designreceptorreceptor expressionresponsesubstance usesubstance use treatmentsuccesstherapeutic candidatetreatment strategy
项目摘要
With currently available medications for opioid use disorder (OUD), the relapse rate is very high. Further, co-
use of an opioid and a stimulant, such as methamphetamine (METH), undermines success in treatment for OUD.
It is highly desired to develop novel therapeutic options for treatment of OUDs including polysubstance use
disorders (PSUDs). Recently reported studies have revealed an interesting role of ghrelin in drug abuse and
reward-relevant behaviors. Ghrelin is known as a “growth-hormone-releasing acylated peptide from stomach”, a
28 amino-acid peptide with the third residue (Ser3) acylated by n-octanoic acid. Ghrelin is produced in the
stomach, travels to the brain through blood circulation, and acts on ghrelin (or growth hormone secretagogue)
receptor (GHSR) to stimulate the mesolimbic dopamine reward pathway and increase rewarding behaviors in
rodents. GHSR antagonism has been shown to attenuate rewarding effects induced by various substances
including METH, amphetamine, fentanyl, morphine, heroin, cocaine, nicotine, and alcohol. For example,
administration of a selective GHSR antagonist significantly reduced the fentanyl‐seeking/relapse‐like behavior
in rats. On the other hand, GHSR has diverse regulatory roles associated with its constitutive activity (the activity
in the absence of ghrelin ligand) and, hence, GHSR antagonism could also result in unwanted adverse effects.
Thus, alternative strategies targeting ghrelin itself could be more interesting. However, whether targeting ghrelin
itself would be effective to attenuate the drug rewarding effects remains controversial in literature as ghrelin
levels before and after treatment were not measured in previous animal studies targeting ghrelin itself. It is
unclear whether any of the previously used approaches was able to decrease the ghrelin level significantly
enough to attenuate the substance reward. We propose to use our recently identified ghrelin deacylase (a mutant
of human butyrylcholinesterase or BChE) as a safe and effective ghrelin modulator to attenuate substance
rewarding effects. Such a ghrelin modulator is expected to be as effective as a GHSR antagonist in treatment of
substance use disorders (SUDs) including PSUDs, but without interacting with any brain receptors/transporters.
Specifically, in this investigation, we will first evaluate the BChE mutant for its in vivo potency in modulating
ghrelin and attenuating the rewarding and reinforcing effects of representative opioids (fentanyl and heroin) and
their combinations with METH in various rodent models. Then, we will design and discover a new BChE mutant
as a more potent ghrelin deacylase with further improved catalytic activity for ghrelin diacylation, develop its
long-acting fusion protein form, and examine the long-term in vivo effects of the long-acting ghrelin deacylase.
Accomplishment of this investigation will determine whether ghrelin itself is a truly effective target and whether
a potent ghrelin deacylase as a ghrelin modulator is truly effective for treatment of PSUDs. If the answers are all
positive, the most effective long-acting ghrelin deacylase (recombinant protein) to be tested and developed may
also serve as a promising therapeutic candidate for treatment of PSUDs.
借助目前可用于用于绿化疾病的药物(OUD),继电器速率非常高。此外,共同
使用阿片类药物和刺激剂,例如甲基苯丙胺(METH),破坏了OUD治疗的成功。
非常希望开发新颖的治疗选择来治疗Oud,包括使用PolySubstance
疾病(psuds)。最近报道的研究表明,生长素释放肽在药物滥用和
与奖励相关的行为。生长素素被称为“从stallch产生的生长激素释放酰化肽”,A
28氨基酸胡椒粉,其第三居住地(Ser3)被N-辛酸酰化。生长素是在
胃,通过血液循环向大脑传播,并作用于生长素(或成长的霍斯纳分泌物)
接收器(GHSR)刺激中比明的多巴胺奖励途径并增加奖励行为
啮齿动物。 GHSR拮抗作用已被证明可以减弱各种物质引起的奖励效应
甲基苯丙胺,苯丙胺,芬太尼,吗啡,海洛因,可卡因,尼古丁和酒精。例如,
选择性GHSR拮抗剂的给药可显着降低寻求芬太尼/复发的行为
在老鼠中。另一方面,GHSR具有与其本构活性相关的潜水调节作用(该活动
在没有生长素蛋白配体的情况下),因此,GHSR拮抗作用也可能导致不良反应。
这是针对生长素本身的替代策略可能会更有趣。但是,是否针对生长素
在ghrelin中,衰减药物奖励效果的衰减本身将有争议
在以前针对生长素蛋白本身的动物研究中,未测量治疗前后的水平。这是
尚不清楚任何先前使用的方法是否能够显着降低生长素素水平
足以减轻物质奖励。我们建议使用我们最近鉴定出的生长素蛋白脱酰基酶(突变体
人丁酰胆碱酯酶或BCHE)作为安全有效的生长素调节剂,可衰减底物
奖励效果。预计这种生长素蛋白调节剂在治疗中与GHSR拮抗剂一样有效
物质使用障碍(SUD),包括psuds,但没有与任何大脑受体/转运蛋白相互作用。
具体而言,在这项调查中,我们将首先评估BCHE突变体的体内效力
生长素并衰减代表性阿片类药物(芬太尼和海洛因)的奖励和增强作用
它们与各种啮齿动物模型中的甲基苯丙胺组合。然后,我们将设计并发现一个新的BCHE突变体
作为具有进一步提高催化活性的尿素二酰基化催化活性的较高潜在的生长素蛋白脱酰基酶,发展其发展
长效融合蛋白形式,并检查长效生长素蛋白脱酰基酶的长期体内效应。
完成这项调查将确定Ghrelin本身是否是真正有效的目标,以及是否是否
潜在的生长素蛋白脱酰基酶作为生长素蛋白调节剂对PSUD的治疗确实有效。如果答案都是
阳性,最有效的长作用生长素蛋白脱酰基酶(重组蛋白)要测试和开发
还可以作为PSUD治疗的有前途的治疗候选者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHANG-GUO ZHAN其他文献
CHANG-GUO ZHAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHANG-GUO ZHAN', 18)}}的其他基金
Long-acting aldicarb hydrolase as a medical countermeasure for aldicarb poisoning
长效涕灭威水解酶作为涕灭威中毒的医学对策
- 批准号:
10724752 - 财政年份:2023
- 资助金额:
$ 170.09万 - 项目类别:
Effects of HIV-1 Tat protein and methamphetamine on VMAT2-mediated dopamine transmission in the context of neuroHIV and drug abuse
HIV-1 Tat 蛋白和甲基苯丙胺对神经 HIV 和药物滥用背景下 VMAT2 介导的多巴胺传递的影响
- 批准号:
10698618 - 财政年份:2023
- 资助金额:
$ 170.09万 - 项目类别:
Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse
开发治疗可卡因滥用的长效酶疗法
- 批准号:
10405101 - 财政年份:2020
- 资助金额:
$ 170.09万 - 项目类别:
Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse
开发治疗可卡因滥用的长效酶疗法
- 批准号:
10231091 - 财政年份:2020
- 资助金额:
$ 170.09万 - 项目类别:
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse
开发长效可卡因水解酶来治疗可卡因滥用
- 批准号:
9754089 - 财政年份:2015
- 资助金额:
$ 170.09万 - 项目类别:
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse
开发长效可卡因水解酶来治疗可卡因滥用
- 批准号:
9139953 - 财政年份:2015
- 资助金额:
$ 170.09万 - 项目类别:
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatment
用于可卡因成瘾治疗的长效可卡因代谢酶
- 批准号:
8636423 - 财政年份:2013
- 资助金额:
$ 170.09万 - 项目类别:
相似国自然基金
基因与家庭不利环境影响儿童反社会行为的表观遗传机制:一项追踪研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
不利地质结构对地下洞室群围岩地震响应影响研究
- 批准号:51009131
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
列车制动力对铁路桥梁的作用机理及最不利影响的研究
- 批准号:50178004
- 批准年份:2001
- 资助金额:23.0 万元
- 项目类别:面上项目
相似海外基金
Impacts of Acute Ambient Air Pollution Exposure on Women's Reproductive Health: Identifying Mechanisms and Susceptible Reproductive Processes Across the Menstrual Cycle and Early Pregnancy
急性环境空气污染暴露对女性生殖健康的影响:确定月经周期和怀孕早期的机制和易受影响的生殖过程
- 批准号:
10645818 - 财政年份:2023
- 资助金额:
$ 170.09万 - 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 170.09万 - 项目类别:
Intermittent Hypoxia Initiated Motor Plasticity in Individuals with Multiple Sclerosis
间歇性缺氧引发多发性硬化症患者的运动可塑性
- 批准号:
10593412 - 财政年份:2023
- 资助金额:
$ 170.09万 - 项目类别:
Processivity and Catalytic Mechanism of Aldosterone Synthase
醛固酮合酶的持续合成能力和催化机制
- 批准号:
10600520 - 财政年份:2023
- 资助金额:
$ 170.09万 - 项目类别:
Perinatal Affective Symptoms, Neuroactive Steroids, and GABA Receptor Plasticity in Women of Color
有色人种女性的围产期情感症状、神经活性类固醇和 GABA 受体可塑性
- 批准号:
10572847 - 财政年份:2023
- 资助金额:
$ 170.09万 - 项目类别: